247 related articles for article (PubMed ID: 25371395)
21. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.
Umiċeviċ Mirkov M; Cui J; Vermeulen SH; Stahl EA; Toonen EJ; Makkinje RR; Lee AT; Huizinga TW; Allaart R; Barton A; Mariette X; Miceli CR; Criswell LA; Tak PP; de Vries N; Saevarsdottir S; Padyukov L; Bridges SL; van Schaardenburg DJ; Jansen TL; Dutmer EA; van de Laar MA; Barrera P; Radstake TR; van Riel PL; Scheffer H; Franke B; Brunner HG; Plenge RM; Gregersen PK; Guchelaar HJ; Coenen MJ
Ann Rheum Dis; 2013 Aug; 72(8):1375-81. PubMed ID: 23233654
[TBL] [Abstract][Full Text] [Related]
23. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy.
Oliveira RD; Fontana V; Junta CM; Marques MM; Macedo C; Rassi DM; Passos GA; Donadi EA; Louzada-Junior P
J Rheumatol; 2012 Aug; 39(8):1524-32. PubMed ID: 22753658
[TBL] [Abstract][Full Text] [Related]
24. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis.
Soubrier M; Jouanel P; Mathieu S; Poujol D; Claus D; Dubost JJ; Ristori JM
Joint Bone Spine; 2008 Jan; 75(1):22-4. PubMed ID: 17888710
[TBL] [Abstract][Full Text] [Related]
25. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
26. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
[TBL] [Abstract][Full Text] [Related]
27. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
Naredo E; Möller I; Cruz A; Carmona L; Garrido J
Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
[TBL] [Abstract][Full Text] [Related]
28. Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.
Brown RA; Spina D; Butt S; Summers GD
Clin Rheumatol; 2012 Mar; 31(3):455-61. PubMed ID: 22009196
[TBL] [Abstract][Full Text] [Related]
29. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
[TBL] [Abstract][Full Text] [Related]
30. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
31. Anti-TNF agents for rheumatoid arthritis.
Seymour HE; Worsley A; Smith JM; Thomas SH
Br J Clin Pharmacol; 2001 Mar; 51(3):201-8. PubMed ID: 11298065
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
Eng G; Stoltenberg MB; Szkudlarek M; Bouchelouche PN; Christensen R; Bliddal H; Marie Bartels E
Semin Arthritis Rheum; 2013 Oct; 43(2):144-51. PubMed ID: 23838092
[TBL] [Abstract][Full Text] [Related]
33. Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy.
McGeough CM; Berrar D; Wright G; Mathews C; Gilmore P; Cunningham RT; Bjourson AJ
Rheumatol Int; 2012 Jun; 32(6):1647-53. PubMed ID: 21373785
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
35. Ultrasound Doppler measurements predict success of treatment with anti-TNF-α drug in patients with rheumatoid arthritis: a prospective cohort study.
Ellegaard K; Christensen R; Torp-Pedersen S; Terslev L; Holm CC; Kønig MJ; Jensen PS; Danneskiold-Samsøe B; Bliddal H
Rheumatology (Oxford); 2011 Mar; 50(3):506-12. PubMed ID: 21071479
[TBL] [Abstract][Full Text] [Related]
36. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
37. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
[TBL] [Abstract][Full Text] [Related]
38. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
39. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
Neovius M; Askling J
Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
[No Abstract] [Full Text] [Related]
40. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A;
Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
